At InterVenn, we're harnessing the power of the glycoproteome to deliver powerful new tools for precision medicine.
Our unique liquid biopsy platform is driving new insights into biomarker discovery, disease detection and progression, therapeutic response, and monitoring
Discover GlycoVisionOur powerful platform comprehensively analyzes glycoproteins by identifying and characterizing their structures, precisely mapping glycosylation sites, and determining specific glycan motifs.
For the first time, we can accurately quantify intact glycopeptides, providing crucial insights into precision medicine events, biological roles, and functions.
We're a liquid biopsy company pioneering the development of clinically useful glycoproteomic diagnostics.
Decoding the glycoproteome: a new frontier for biomarker discovery in cancer
Journal of Hematology & Oncology | March 22, 2024
Early Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling
Gastroenterology | September 25, 2023
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
Frontier in Immunology | June 13, 2023